120 related articles for article (PubMed ID: 37179506)
1. Upfront surgery for N2 NSCLC: a large retrospective multicenter cohort study.
Campisi A; Catelli C; Gabryel P; Giovannetti R; Dell'Amore A; Kasprzyk M; Piwkowski C; Infante M
Gen Thorac Cardiovasc Surg; 2023 Dec; 71(12):715-722. PubMed ID: 37179506
[TBL] [Abstract][Full Text] [Related]
2. Comparison of mediastinal lymph node status and relapse pattern in clinical stage IIIA non-small cell lung cancer patients treated with neoadjuvant chemotherapy versus upfront surgery: A single center experience.
Savic M; Kontic M; Ercegovac M; Stojsic J; Bascarevic S; Moskovljevic D; Kostic M; Vesovic R; Popevic S; Laban M; Markovic J; Jovanovic D
Thorac Cancer; 2017 Sep; 8(5):393-401. PubMed ID: 28671758
[TBL] [Abstract][Full Text] [Related]
3. Mediastinal Up-Staging During Surgery in Non-Small-Cell Lung Cancer: Which Mediastinal Lymph Node Metastasis Patterns Better Predict The Outcome? A Multicenter Analysis.
Chiappetta M; Leuzzi G; Sperduti I; Bria E; Mucilli F; Lococo F; Filosso PL; Ratto GB; Spaggiari L; Facciolo F
Clin Lung Cancer; 2020 Sep; 21(5):464-471.e1. PubMed ID: 32389508
[TBL] [Abstract][Full Text] [Related]
4. Upfront surgery as first-line therapy in selected patients with stage IIIA non-small cell lung cancer.
Zheng D; Ye T; Hu H; Zhang Y; Sun Y; Xiang J; Chen H
J Thorac Cardiovasc Surg; 2018 Apr; 155(4):1814-1822.e4. PubMed ID: 29221745
[TBL] [Abstract][Full Text] [Related]
5. Survival outcome of upfront surgery for clinical single-station N2 non-small cell lung cancer.
Hayakawa T; Isaka M; Konno H; Mizuno T; Kawata T; Kenmotsu H; Takahashi T; Ohde Y
Jpn J Clin Oncol; 2023 Apr; 53(5):429-435. PubMed ID: 36655315
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcomes of upfront surgery in patients with resectable pathological N2 non-small-cell lung cancer.
Yun JK; Bok JS; Lee GD; Kim HR; Kim YH; Kim DK; Park SI; Choi S
Eur J Cardiothorac Surg; 2020 Jul; 58(1):59-69. PubMed ID: 32155245
[TBL] [Abstract][Full Text] [Related]
7. Role of postoperative radiotherapy after curative resection and adjuvant chemotherapy for patients with pathological stage N2 non-small-cell lung cancer: a propensity score matching analysis.
Kim BH; Kim HJ; Wu HG; Kang CH; Kim YT; Lee SH; Kim DW
Clin Lung Cancer; 2014 Sep; 15(5):356-64. PubMed ID: 24996882
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant therapy following induction therapy and surgery improves survival in N2-positive non-small cell lung cancer.
White AA; Lee DN; Mazzola E; Kucukak S; Polhemus E; Jaklitsch MT; Mentzer SJ; Wee JO; Bueno R; Swanson SJ
J Surg Oncol; 2021 Feb; 123(2):579-586. PubMed ID: 33259637
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors of T2aN0M0 (T3-4cmN0M0, stage IB) non-small-cell lung cancer after surgery: Single-center real-world research.
Liu L; Zhang J; Wang G; Zhao K; Guo C; Chen Y; Huang C; Li S
Thorac Cancer; 2021 Dec; 12(24):3319-3326. PubMed ID: 34734467
[TBL] [Abstract][Full Text] [Related]
10. Postoperative radiotherapy with modern techniques does not improve survival for operable stage IIIA-N2 non-small cell lung cancer.
Predina J; Suliman R; Potter AL; Panda N; Diao K; Lanuti M; Muniappan A; Jeffrey Yang CF
J Thorac Cardiovasc Surg; 2023 May; 165(5):1696-1709.e4. PubMed ID: 36610886
[TBL] [Abstract][Full Text] [Related]
11. Postoperative radiotherapy for pathological stage IIIA-N2 non-small cell lung cancer with positive surgical margins.
Yuan M; Men Y; Kang J; Sun X; Zhao M; Bao Y; Yang X; Sun S; Ma Z; Wang J; Deng L; Wang W; Zhai Y; Liu W; Zhang T; Wang X; Bi N; Lv J; Liang J; Feng Q; Chen D; Xiao Z; Zhou Z; Wang L; Hui Z
Thorac Cancer; 2021 Jan; 12(2):227-234. PubMed ID: 33247556
[TBL] [Abstract][Full Text] [Related]
12. Long-term clinical outcomes and prognostic factors of upfront surgery as a first-line therapy in biopsy-proven clinical N2 non-small cell lung cancer.
Bertolaccini L; Prisciandaro E; Guarize J; Girelli L; Sedda G; Filippi N; de Marinis F; Spaggiari L
Front Oncol; 2022; 12():933278. PubMed ID: 35965495
[TBL] [Abstract][Full Text] [Related]
13. A multicenter retrospective analysis of survival outcome following postoperative chemoradiotherapy in non-small-cell lung cancer patients with N2 nodal disease.
Zou B; Xu Y; Li T; Li W; Tang B; Zhou L; Li L; Liu Y; Zhu J; Huang M; Wang J; Ren L; Gong Y; Che G; Liu L; Hou M; Lu Y
Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):321-8. PubMed ID: 19775829
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Significance of the Number of Metastatic pN2 Lymph Nodes in Stage IIIA-N2 Non-Small-Cell Lung Cancer After Curative Resection.
Yoo C; Yoon S; Lee DH; Park SI; Kim DK; Kim YH; Kim HR; Choi SH; Kim WS; Choi CM; Jang SJ; Song SY; Kim SS; Choi EK; Lee JC; Suh C; Lee JS; Kim SW
Clin Lung Cancer; 2015 Nov; 16(6):e203-12. PubMed ID: 25997733
[TBL] [Abstract][Full Text] [Related]
15. [Comparative study on prognosis of neoadjuvant chemotherapy followed by hepatic surgery versus upfront surgery in patients with synchronous colorectal liver metastasis].
Wang LJ; Wang HW; Jin KM; Liu W; Bao Q; Wang K; Xing BC
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):248-255. PubMed ID: 34645169
[No Abstract] [Full Text] [Related]
16. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival.
Decaluwé H; De Leyn P; Vansteenkiste J; Dooms C; Van Raemdonck D; Nafteux P; Coosemans W; Lerut T
Eur J Cardiothorac Surg; 2009 Sep; 36(3):433-9. PubMed ID: 19502079
[TBL] [Abstract][Full Text] [Related]
17. Surgical therapeutic strategy for non-small cell lung cancer with mediastinal lymph node metastasis (N2).
Ma Q; Liu D; Guo Y; Shi B; Song Z; Tian Y
Zhongguo Fei Ai Za Zhi; 2010 Apr; 13(4):342-8. PubMed ID: 20677562
[TBL] [Abstract][Full Text] [Related]
18. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemoradiotherapy is superior to chemotherapy alone in surgically treated stage III/N2 non-small-cell lung cancer: a retrospective single-center cohort study.
Sinn K; Mosleh B; Steindl A; Zoechbauer-Mueller S; Dieckmann K; Widder J; Steiner E; Klepetko W; Hoetzenecker K; Laszlo V; Doeme B; Klikovits T; Hoda MA
ESMO Open; 2022 Apr; 7(2):100466. PubMed ID: 35397435
[TBL] [Abstract][Full Text] [Related]
20. Postoperative chemoradiotherapy is superior to postoperative chemotherapy alone in squamous cell lung cancer patients with limited N2 lymph node metastasis.
Su L; Chen M; Su H; Dai Y; Chen S; Li J
BMC Cancer; 2019 Oct; 19(1):1023. PubMed ID: 31666026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
